Does the media refer more to ISRG or SYK?

In the previous week, Intuitive Surgical had 30 more articles in the media than Stryker. MarketBeat recorded 65 mentions for Intuitive Surgical and 35 mentions for Stryker. Intuitive Surgical's average media sentiment score of 1.51 beat Stryker's score of 1.50 indicating that Intuitive Surgical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intuitive Surgical 60 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Very Positive Stryker 32 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BSX or SYK?

In the previous week, Boston Scientific had 11 more articles in the media than Stryker. MarketBeat recorded 46 mentions for Boston Scientific and 35 mentions for Stryker. Boston Scientific's average media sentiment score of 1.51 beat Stryker's score of 1.50 indicating that Boston Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 42 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive Stryker 32 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to CAH or SYK?

In the previous week, Stryker had 27 more articles in the media than Cardinal Health. MarketBeat recorded 35 mentions for Stryker and 8 mentions for Cardinal Health. Stryker's average media sentiment score of 1.50 beat Cardinal Health's score of 0.93 indicating that Stryker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardinal Health 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Stryker 32 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, SYK or COR?

Stryker has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stryker $25.12B 4.71 $3.25B $8.64 35.72 Cencora $638.56M 82.87 $1.55B $13.04 20.86

Is SYK or COR more profitable?

Stryker has a net margin of 13.20% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Stryker's return on equity. Company Net Margins Return on Equity Return on Assets Stryker 13.20% 23.42% 11.04% Cencora 0.78% 135.20% 4.20%

Does the media prefer SYK or COR?

In the previous week, Stryker had 30 more articles in the media than Cencora. MarketBeat recorded 35 mentions for Stryker and 5 mentions for Cencora. Stryker's average media sentiment score of 1.50 beat Cencora's score of 0.75 indicating that Stryker is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stryker 32 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Very Positive Cencora 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, DVA or SYK?

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.98 $746.80M $10.78 19.26 Stryker $25.12B 4.71 $3.25B $8.64 35.72

Is DVA or SYK more profitable?

Stryker has a net margin of 13.20% compared to DaVita's net margin of 5.65%. Stryker's return on equity of 23.42% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 5.65% -270.37% 4.87% Stryker 13.20% 23.42% 11.04%

Does the media refer more to DVA or SYK?

In the previous week, Stryker had 24 more articles in the media than DaVita. MarketBeat recorded 35 mentions for Stryker and 11 mentions for DaVita. Stryker's average media sentiment score of 1.50 beat DaVita's score of 0.73 indicating that Stryker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stryker 32 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Very Positive

Stryker (SYK) Competitors

$308.62 +0.82 (+0.26%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$307.50 -1.11 (-0.36%)

As of 06/18/2026 07:38 PM Eastern

Compare

SYK vs. ISRG, BSX, CAH, COR, and DVA

Should you buy Stryker stock or one of its competitors? MarketBeat compares Stryker with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Stryker include Intuitive Surgical (ISRG), Boston Scientific (BSX), Cardinal Health (CAH), Cencora (COR), and DaVita (DVA). These companies are all part of the "medical" sector.

How does Stryker compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Intuitive Surgical has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Stryker has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Stryker has higher revenue and earnings than Intuitive Surgical. Stryker is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.06B	14.31	$2.86B	$8.25	49.31
Stryker	$25.12B	4.71	$3.25B	$8.64	35.72

In the previous week, Intuitive Surgical had 30 more articles in the media than Stryker. MarketBeat recorded 65 mentions for Intuitive Surgical and 35 mentions for Stryker. Intuitive Surgical's average media sentiment score of 1.51 beat Stryker's score of 1.50 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	60 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Stryker	32 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Very Positive

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 4.6% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Intuitive Surgical has a net margin of 28.15% compared to Stryker's net margin of 13.20%. Stryker's return on equity of 23.42% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
Stryker	13.20%	23.42%	11.04%

Intuitive Surgical currently has a consensus target price of $573.42, indicating a potential upside of 40.96%. Stryker has a consensus target price of $395.33, indicating a potential upside of 28.10%. Given Intuitive Surgical's higher probable upside, equities analysts clearly believe Intuitive Surgical is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.67
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Intuitive Surgical beats Stryker on 10 of the 16 factors compared between the two stocks.

How does Stryker compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Stryker has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.35	$2.90B	$2.39	18.95
Stryker	$25.12B	4.71	$3.25B	$8.64	35.72

Boston Scientific presently has a consensus target price of $85.08, indicating a potential upside of 87.81%. Stryker has a consensus target price of $395.33, indicating a potential upside of 28.10%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities analysts plainly believe Boston Scientific is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	1 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.80
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by insiders. Comparatively, 4.6% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Boston Scientific had 11 more articles in the media than Stryker. MarketBeat recorded 46 mentions for Boston Scientific and 35 mentions for Stryker. Boston Scientific's average media sentiment score of 1.51 beat Stryker's score of 1.50 indicating that Boston Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	42 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Positive
Stryker	32 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Boston Scientific has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Boston Scientific has a net margin of 17.29% compared to Stryker's net margin of 13.20%. Stryker's return on equity of 23.42% beat Boston Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.29%	19.17%	10.77%
Stryker	13.20%	23.42%	11.04%

Summary

Stryker beats Boston Scientific on 9 of the 17 factors compared between the two stocks.

How does Stryker compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Stryker had 27 more articles in the media than Cardinal Health. MarketBeat recorded 35 mentions for Stryker and 8 mentions for Cardinal Health. Stryker's average media sentiment score of 1.50 beat Cardinal Health's score of 0.93 indicating that Stryker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Stryker	32 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Stryker has lower revenue, but higher earnings than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$222.58B	0.23	$1.56B	$6.54	33.96
Stryker	$25.12B	4.71	$3.25B	$8.64	35.72

Cardinal Health has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Cardinal Health pays out 31.2% of its earnings in the form of a dividend. Stryker pays out 40.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years and Stryker has raised its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has a net margin of 13.20% compared to Cardinal Health's net margin of 0.62%. Stryker's return on equity of 23.42% beat Cardinal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.62%	-92.61%	4.46%
Stryker	13.20%	23.42%	11.04%

Cardinal Health currently has a consensus target price of $246.93, indicating a potential upside of 11.19%. Stryker has a consensus target price of $395.33, indicating a potential upside of 28.10%. Given Stryker's higher possible upside, analysts plainly believe Stryker is more favorable than Cardinal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.1% of Cardinal Health shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Stryker beats Cardinal Health on 15 of the 19 factors compared between the two stocks.

How does Stryker compare to Cencora?

Stryker (NYSE:SYK) and Cencora (NYSE:COR) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Stryker has a net margin of 13.20% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Stryker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	13.20%	23.42%	11.04%
Cencora	0.78%	135.20%	4.20%

Stryker has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$25.12B	4.71	$3.25B	$8.64	35.72
Cencora	$638.56M	82.87	$1.55B	$13.04	20.86

Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Cencora has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.9%. Stryker pays out 40.7% of its earnings in the form of a dividend. Cencora pays out 18.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 32 consecutive years and Cencora has increased its dividend for 15 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Stryker had 30 more articles in the media than Cencora. MarketBeat recorded 35 mentions for Stryker and 5 mentions for Cencora. Stryker's average media sentiment score of 1.50 beat Cencora's score of 0.75 indicating that Stryker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	32 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cencora	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stryker currently has a consensus target price of $395.33, suggesting a potential upside of 28.10%. Cencora has a consensus target price of $374.00, suggesting a potential upside of 37.51%. Given Cencora's stronger consensus rating and higher probable upside, analysts clearly believe Cencora is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cencora	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.80

77.1% of Stryker shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 4.6% of Stryker shares are held by company insiders. Comparatively, 0.4% of Cencora shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Stryker beats Cencora on 12 of the 19 factors compared between the two stocks.

How does Stryker compare to DaVita?

DaVita (NYSE:DVA) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

DaVita currently has a consensus target price of $199.17, indicating a potential downside of 4.08%. Stryker has a consensus target price of $395.33, indicating a potential upside of 28.10%. Given Stryker's stronger consensus rating and higher probable upside, analysts clearly believe Stryker is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Stryker had 24 more articles in the media than DaVita. MarketBeat recorded 35 mentions for Stryker and 11 mentions for DaVita. Stryker's average media sentiment score of 1.50 beat DaVita's score of 0.73 indicating that Stryker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stryker	32 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Very Positive

DaVita has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Stryker has a net margin of 13.20% compared to DaVita's net margin of 5.65%. Stryker's return on equity of 23.42% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Stryker	13.20%	23.42%	11.04%

90.1% of DaVita shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 1.5% of DaVita shares are owned by company insiders. Comparatively, 4.6% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.98	$746.80M	$10.78	19.26
Stryker	$25.12B	4.71	$3.25B	$8.64	35.72

Summary

Stryker beats DaVita on 13 of the 17 factors compared between the two stocks.

Get Stryker News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYK vs. The Competition

Export

Metric	Stryker	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$118.00B	$8.34B	$6.43B	$23.20B
Dividend Yield	1.14%	2.55%	2.68%	4.06%
P/E Ratio	35.72	15.57	24.75	31.61
Price / Sales	4.71	7.37	533.15	112.08
Price / Cash	18.22	17.05	45.07	24.44
Price / Book	5.26	3.28	10.80	4.68
Net Income	$3.25B	$224.06M	$3.57B	$1.08B
7 Day Performance	-1.13%	-1.92%	0.72%	-0.82%
1 Month Performance	-1.55%	-2.90%	0.41%	1.07%
1 Year Performance	-17.80%	0.83%	29.34%	25.02%

Stryker Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYK Stryker	4.918 of 5 stars	$308.62 +0.3%	$395.33 +28.1%	-17.8%	$118.00B	$25.12B	35.72	56,000	News Coverage Positive News Gap Down
ISRG Intuitive Surgical	4.3175 of 5 stars	$418.58 -0.8%	$573.63 +37.0%	-20.1%	$148.25B	$10.58B	50.74	17,021	News Coverage Positive News
BSX Boston Scientific	4.9493 of 5 stars	$48.73 +0.4%	$85.92 +76.3%	-55.3%	$72.42B	$20.61B	20.39	59,000	Positive News Analyst Forecast
CAH Cardinal Health	4.3819 of 5 stars	$204.56 -0.6%	$241.80 +18.2%	+36.2%	$47.91B	$222.58B	31.28	57,700	News Coverage
COR Cencora	4.7944 of 5 stars	$274.04 -0.4%	$380.25 +38.8%	-7.4%	$53.32B	$321.33B	21.02	51,000	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SYK) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Competitors

SYK vs. ISRG, BSX, CAH, COR, and DVA

How does Stryker compare to Intuitive Surgical?

Summary

How does Stryker compare to Boston Scientific?

Summary

How does Stryker compare to Cardinal Health?

Summary

How does Stryker compare to Cencora?

Summary

How does Stryker compare to DaVita?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYK vs. The Competition

Stryker Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stryker (SYK) Competitors

SYK vs. ISRG, BSX, CAH, COR, and DVA

How does Stryker compare to Intuitive Surgical?

Which has more risk and volatility, ISRG or SYK?

Which has higher valuation and earnings, ISRG or SYK?

Does the media refer more to ISRG or SYK?

Do institutionals and insiders believe in ISRG or SYK?

Is ISRG or SYK more profitable?

Do analysts rate ISRG or SYK?

Summary

How does Stryker compare to Boston Scientific?

Which has preferable valuation and earnings, BSX or SYK?

Do analysts prefer BSX or SYK?

Do institutionals and insiders believe in BSX or SYK?

Does the media refer more to BSX or SYK?

Which has more volatility and risk, BSX or SYK?

Is BSX or SYK more profitable?

Summary

How does Stryker compare to Cardinal Health?

Does the media refer more to CAH or SYK?

Which has better earnings and valuation, CAH or SYK?

Which has more risk and volatility, CAH or SYK?

Is CAH or SYK a better dividend stock?

Is CAH or SYK more profitable?

Do analysts recommend CAH or SYK?

Do institutionals & insiders believe in CAH or SYK?

Summary

How does Stryker compare to Cencora?

Is SYK or COR more profitable?

Which has stronger earnings & valuation, SYK or COR?

Which has more volatility & risk, SYK or COR?

Is SYK or COR a better dividend stock?

Does the media prefer SYK or COR?

Do analysts recommend SYK or COR?

Do insiders & institutionals have more ownership in SYK or COR?

Summary

How does Stryker compare to DaVita?

Do analysts rate DVA or SYK?

Does the media refer more to DVA or SYK?

Which has more risk & volatility, DVA or SYK?

Is DVA or SYK more profitable?

Do institutionals & insiders have more ownership in DVA or SYK?

Which has better earnings & valuation, DVA or SYK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYK vs. The Competition

Stryker Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools